Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies

키워드

참고문헌 (20)

1. Freifeld AG, "Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America", Clin Infect Dis, 52, pp.e56~e93 (2011)
2. Cornely OA, "Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia", N Engl J Med, 356, pp.348~359 (2007)
3. Torres HA, "Posaconazole: a broad-spectrum triazole antifungal", Lancet Infect Dis, 5, pp.775~785 (2005)
4. Chae H, "Determination of posaconazole concentration with LC-MS", MS in adult patients with hematologic malignancy, 2015, pp.450, 220~226
5. Dolton MJ, "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration", Antimicrob Agents Chemother, 56, pp.5503~5510 (2012)
6. Hoenigl M, "Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies", Int J Antimicrob Agents, 39, pp.510~513 (2012)
7. 강승훈, "Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis", Infection and Chemotherapy, 47(1), pp.49~54 (2015), 대한감염학회
8. Guarascio AJ, "Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole", Pharmacotherapy, 35, pp.208~219 (2015)
9. McKeage K, "Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections", Drugs, 75, pp.397~406 (2015)
10. Krishna G, "A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single-and multiple- dose pharmacokinetics and safety in healthy volunteers", J Antimicrob Chemother, 67, pp.2725~2730 (2012)
11. Park WB, "Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy", Int J Antimicrob Agents, 48, pp.106~110 (2016)
12. Jang SH, "Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma", Clin Pharmacol Ther, 88, pp.115~119 (2010)
13. Ashbee HR, "Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology", J Antimicrob Chemother, 69, pp.1162~1176 (2014)
14. Wiederhold NP, "Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections", Clin Pharmacol, 8, pp.1~8 (2015)
15. Common terminology criteria for adverse events (CTCAE) version 4.0, "US Department of Health and Human Services", National Cancer Institute, ~, pp.NIH publication No. 09-5410 (2009)
16. Moton A, "Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers", J Clin Pharm Ther, 34, pp.301~311 (2009)
17. Catanzaro A, "Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis", Clin Infect Dis, 45, pp.562~568 (2007)
18. Pham AN, "Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections", Mycoses (2016)
19. Cornely OA, "Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease", J Antimicrob Chemother, 71, pp.718~726 (2016)
20. Jung DS, "Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity", Antimicrob Agents Chemother, 58, pp.6993~6995 (2014)

관련 논문AI추천